AI
AERI

Axiom Investors’s Aerie Pharmaceuticals AERI Stock Holding History

Axiom Investors’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-40,614
Closed -$2.2M – 164
2018
Q1 		$2.2M Sell
40,614
-4,075
-9% -$228K 0.05% 116
2017
Q4 		$2.67M Buy
44,689
+1,627
+4% +$98.7K 0.07% 108
2017
Q3 		$2.09M Buy
+43,062
New +$2.35M 0.05% 119

Other funds holding AERI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Axiom Investors's AERI Position: Q2 2018 in Review

Axiom Investors sold out of Aerie Pharmaceuticals (AERI) in Q2 2018, closing a stake of 40,614 shares — an estimated $2.2M sold.

Axiom Investors first reported a position in AERI in Q3 2017 and held it in 3 quarters. The position peaked at $2.67M in Q4 2017. 175 funds tracked by Wall St. Rank hold AERI as of Q2 2018.

  • Axiom Investors reported no remaining Aerie Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Axiom Investors sold 40,614 Aerie Pharmaceuticals shares in Q2 2018, an estimated $2.2M.
  • Axiom Investors first reported a position in Aerie Pharmaceuticals in Q3 2017 and held it in 3 quarters.
  • Axiom Investors's Aerie Pharmaceuticals position peaked at $2.67M in Q4 2017.
  • 175 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q2 2018.

Based on Axiom Investors's 13F filing for Q2 2018, filed 13 Aug 2018.